All Stories

Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy

Lexeo Therapeutics has posted updated data in Friedreich ataxia patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a registrational trial.

Apr 7, 2025 - 15:18
 0
Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy
Lexeo Therapeutics has posted updated data in Friedreich ataxia patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a registrational trial.
Read More

Tags:

Previous Article

Latvian Government Ousts AirBaltic CEO Martin Gauss

Next Article

Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2025, European Me...

Related Posts

Fierce Biotech Fundraising Tracker '25: RayThera raises $110M series A; Neurona nabs $102M

Fierce Biotech Fundraising Tracker '25: RayThera raises...

Apr 4, 2025  0

RFK Jr. cuts 4,700 FDA and NIH jobs as HHS eliminates ‘an entire alphabet soup of departments’

RFK Jr. cuts 4,700 FDA and NIH jobs as HHS eliminates ‘...

Mar 27, 2025  0

Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline

Biogen pays Stoke $165M, bagging Dravet prospect to fir...

Feb 18, 2025  0